Skip to content
  • Home Home Home, current page.
  • Moments Moments Moments, current page.

Saved searches

  • Remove
  • In this conversation
    Verified accountProtected Tweets @
Suggested users
  • Verified accountProtected Tweets @
  • Verified accountProtected Tweets @
  • Language: English
    • Bahasa Indonesia
    • Bahasa Melayu
    • Català
    • Čeština
    • Dansk
    • Deutsch
    • English UK
    • Español
    • Filipino
    • Français
    • Hrvatski
    • Italiano
    • Magyar
    • Nederlands
    • Norsk
    • Polski
    • Português
    • Română
    • Slovenčina
    • Suomi
    • Svenska
    • Tiếng Việt
    • Türkçe
    • Ελληνικά
    • Български език
    • Русский
    • Српски
    • Українська мова
    • עִבְרִית
    • العربية
    • فارسی
    • मराठी
    • हिन्दी
    • বাংলা
    • ગુજરાતી
    • தமிழ்
    • ಕನ್ನಡ
    • ภาษาไทย
    • 한국어
    • 日本語
    • 简体中文
    • 繁體中文
  • Have an account? Log in
    Have an account?
    · Forgot password?

    New to Twitter?
    Sign up
michaelmina_lab's profile
Michael Mina
Michael Mina
Michael Mina
Verified account
@michaelmina_lab

Tweets

Michael MinaVerified account

@michaelmina_lab

Epidemiologist, Immunologist, Pathologist, MD,PhD Discuss vaccines, immunity, infectious diseases, tests, public health Chief Science Officer@eMedCertified

Boston, MA
Joined February 2019

Tweets

  • © 2022 Twitter
  • About
  • Help Center
  • Terms
  • Privacy policy
  • Cookies
  • Ads info
Dismiss
Previous
Next

Go to a person's profile

Saved searches

  • Remove
  • In this conversation
    Verified accountProtected Tweets @
Suggested users
  • Verified accountProtected Tweets @
  • Verified accountProtected Tweets @

Promote this Tweet

Block

  • Tweet with a location

    You can add location information to your Tweets, such as your city or precise location, from the web and via third-party applications. You always have the option to delete your Tweet location history. Learn more

    Your lists

    Create a new list


    Under 100 characters, optional

    Privacy

    Copy link to Tweet

    Embed this Tweet

    Embed this Video

    Add this Tweet to your website by copying the code below. Learn more

    Add this video to your website by copying the code below. Learn more

    Hmm, there was a problem reaching the server.

    By embedding Twitter content in your website or app, you are agreeing to the Twitter Developer Agreement and Developer Policy.

    Preview

    Why you're seeing this ad

    Log in to Twitter

    · Forgot password?
    Don't have an account? Sign up »

    Sign up for Twitter

    Not on Twitter? Sign up, tune into the things you care about, and get updates as they happen.

    Sign up
    Have an account? Log in »

    Two-way (sending and receiving) short codes:

    Country Code For customers of
    United States 40404 (any)
    Canada 21212 (any)
    United Kingdom 86444 Vodafone, Orange, 3, O2
    Brazil 40404 Nextel, TIM
    Haiti 40404 Digicel, Voila
    Ireland 51210 Vodafone, O2
    India 53000 Bharti Airtel, Videocon, Reliance
    Indonesia 89887 AXIS, 3, Telkomsel, Indosat, XL Axiata
    Italy 4880804 Wind
    3424486444 Vodafone
    » See SMS short codes for other countries

    Confirmation

     

    Welcome home!

    This timeline is where you’ll spend most of your time, getting instant updates about what matters to you.

    Tweets not working for you?

    Hover over the profile pic and click the Following button to unfollow any account.

    Say a lot with a little

    When you see a Tweet you love, tap the heart — it lets the person who wrote it know you shared the love.

    Spread the word

    The fastest way to share someone else’s Tweet with your followers is with a Retweet. Tap the icon to send it instantly.

    Join the conversation

    Add your thoughts about any Tweet with a Reply. Find a topic you’re passionate about, and jump right in.

    Learn the latest

    Get instant insight into what people are talking about now.

    Get more of what you love

    Follow more accounts to get instant updates about topics you care about.

    Find what's happening

    See the latest conversations about any topic instantly.

    Never miss a Moment

    Catch up instantly on the best stories happening as they unfold.

    1. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

      VACCINES can work! Another #COVID19 phase 3 vaccine trial reports awesome results. This time, an estimated 94% efficacy 95 COVID19 detected: only 5! in the vaccine group and 90 in the placebo But like Pfizer results - need to take w caution... WHY? 1/ https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy …

      87 replies 543 retweets 1,980 likes
      Show this thread
    2. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

      First, the amazing efficacy from phase 3 at this point for both @moderna_tx and @pfizer vaccines - both mRNA vaccines - is EXCEEDINGLY ENCOURAGING. These results show that these vaccines are eliciting the correct antibody bases responses to stop symptomatic infection! 2/

      4 replies 38 retweets 411 likes
      Show this thread
    3. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

      What I am worried about is the time scale of the trials thus far: The leading vaccines are presenting the spike protein to the human immune system. This makes sense! Immunize against spike and stop virus entry into the cells. 3/

      6 replies 36 retweets 375 likes
      Show this thread
    4. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

      But that these vaccines are designed specifically around antibody based responses suggest these early phase 3 endpoints - which are detected within a couple of months of getting the vaccine - may be enjoying a major but temporary boost from the early vaccine effects 4/

      5 replies 42 retweets 407 likes
      Show this thread
    5. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

      When you get an infection or a vaccine, the body makes a HUGE number of temporary antibody secreting cells called plasmablasts. These are evolutionarily “designed” to infuse a huge and robust antibody response capable of clearing an active infection 5/

      1 reply 37 retweets 403 likes
      Show this thread
    6. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

      But over the month or so after the infection or vaccine, the plasmablasts have to die off - it is their fate. Over the coming weeks and months so too do the antibodies they produced. What remains after is usually a much smaller antibody producing cellular subset 6/

      4 replies 34 retweets 410 likes
      Show this thread
      Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

      So I am a bit hesitant to jump on board with the >90% efficacy results because the time scale of the phase 3 studies thus far match the time scale of the temporary plasmablast duration and the antibodies they produced... 7/

      7:13 AM - 16 Nov 2020
      • 83 Retweets
      • 630 Likes
      • JessR Pam Vashti Bandy Jeffrey Townsend John Decker The Sosa Bre Takeshi Kovac Postcards from the burbs.... DADDLY 🥋
      8 replies 83 retweets 630 likes
        1. New conversation
        2. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

          So, w these early efficacy results, we may be measuring the effects of an impressive front line army that spins up in response to the vaccine - but then we should be careful not to assume the same efficacy persists to hold that line after most of the troops disappear! 8/

          17 replies 52 retweets 635 likes
          Show this thread
        3. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

          That all said - what these two vaccines show is they hit the nail on the head to find the right protein to immunize against! Only time and careful follow up will tell how much the >90% efficacy of the two vaccines holds after the early vaccine responses fade away. 9/

          11 replies 45 retweets 533 likes
          Show this thread
        4. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

          This is btw generally why we must monitor durability of vaccine responses over time. And why we have to always be careful to interpret efficacy within the parameters of the data we have (here - early months post vaccine) Also - we don’t know about transmission blocking... 10/

          7 replies 39 retweets 568 likes
          Show this thread
        5. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

          To learn about the actual benefits long term of the vaccine reaponse - it will take continued post market analysis. The controls will likely get the vaccine - so a new type of vaccine study that is not as well controlled will ensue to measure longer term effects. 11/

          10 replies 30 retweets 378 likes
          Show this thread
        6. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

          Also - I’m not speaking in black and white terms here. Either way, immunity will likely persist. It’s not binary. B and T cells are produced At population level, we must wait to see if 94% efficacy to fully block symptomatic disease becomes 90% or if it becomes 50%, or 30% 12/

          4 replies 48 retweets 487 likes
          Show this thread
        7. Michael Mina‏Verified account @michaelmina_lab 16 Nov 2020

          And even if it becomes 50% to stop total symptomatic disease, it could remain 90% to stop severe disease. This, like testing and everything else is simply NOT a binary issue and also is NOT a simple issue meant for describing over Twitter.... 13/

          55 replies 73 retweets 989 likes
          Show this thread
        8. End of conversation
        1. HarshT‏ @harsht 16 Nov 2020
          Replying to @michaelmina_lab

          If protection is indeed short lived, should our strategy be to first vaccinate "potential" super-spreaders? Basically nodes whose immunity would break several transmission chains e.g., Clergies, nurses, resident doctors, nursing home staff, front facing grocery employees?

          0 replies 0 retweets 5 likes
          Thanks. Twitter will use this to make your timeline better. Undo
          Undo
        1. New conversation
        2. Good Grief‏ @20GoodGrief16 17 Nov 2020
          Replying to @michaelmina_lab

          Question, are they calculating an efficacy rate based on a percentage of the population receiving the vaccine? Its widely known Vac's don't work as well on the older and rely heavily on high % of pop receiving.

          2 replies 0 retweets 0 likes
        3. Pratik‏ @Pratik_1984 21 Nov 2020
          Replying to @20GoodGrief16 @michaelmina_lab

          Pfizer also trialled over 65s and concluded 94% protection vs 95 with the complete group.

          0 replies 0 retweets 1 like
        4. End of conversation
        1. #CharlesDeservedToLive‏ @LolaMotz 21 Nov 2020
          Replying to @michaelmina_lab

          How often would the vaccine need to be repeated to get the pandemic under control and do we have the capacity for making enough doses for repeat vaccinations?

          0 replies 0 retweets 3 likes
          Thanks. Twitter will use this to make your timeline better. Undo
          Undo

      Loading seems to be taking a while.

      Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.

        Promoted Tweet

        false

        • © 2022 Twitter
        • About
        • Help Center
        • Terms
        • Privacy policy
        • Cookies
        • Ads info